Latest Updates
-
Hiroshima Day: Five Medical Discoveries That Emerged From One of History's Greatest Tragedies -
Why Young Adults Ignore Persistent Swelling for Months — And When It May Be Sarcoma -
Bigg Boss 20 Premiere Date Out: Salman Khan's Karan Arjun Tease Sparks SRK Buzz -
India's 101st Ramsar Site: What's Special About Arunachal Pradesh's Glaw Lake -
Gujarat's Chandipura Virus Outbreak: 22 Children Dead, Here's What Parents Must Know -
Can Gym Supplements and Unsafe Injections Damage the Liver? Expert Explains -
Pradeep Rawat Dies At 74: Inside His Five-Year Fight With Blood Cancer -
Masik Kalashtami August 2026: Significance, Puja Timings, Rituals And Why Lord Kala Bhairava Is Worshipped -
Why AAFT University Is Emerging as a Preferred Destination for Journalism Education in India -
AAFT Noida Trains Journalism Students on MSTV and AAFT24x7 Before They Enter Real Newsrooms
Serum Institute Seeks DCGI Nod For COVID Vaccine Covovax
The Serum Institute of India on Friday sought permission from the Drugs Controller General of India (DCGI) to manufacture COVID-19 vaccine Covovax for restricted use in emergency situations at its Manjari manufacturing site, official sources said.

The company has submitted an interim phase 2/3 clinical study report on Indian adults, the interim report of Novavax UK and USA-Mexico phase-3 clinical study and response to the queries raised by the DCGI office, along with its application.
There were no safety concerns arising from the study data and Covovax is safe and immunogenic in the adult population, Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Serum Institute of India (SII), is learnt to have said in the application sent to the DCGI.
"In our government's endeavour to fight against COVID-19 pandemic, we have also been working shoulder to shoulder with the Government of India to make available one more safe and efficacious world-class COVID-19 vaccine for our country and the world at large."
"Approval of our COVOVAX and its availability will further strengthen India's capability to fight COVID-19 pandemic and ensure vaccine security in line with our prime minister's clarion call of Atmanirbhar Bharat," an official source quoted Singh as having said in the application.
In the phase 2/3 study in India, more than 1,400 participants have received at least the first dose of the vaccine with no safety concerns reported so far, stated the application.
In August 2020, US-based vaccine maker Novavax Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
SII, which manufactures Covishield, plans to produce Covovax at its Manjari plant in Maharashtra.
India has given emergency use permission to several COVID-19 vaccines, including Covishield, Covaxin of Bharat Biotech and Russian-made Sputnik V.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications